Opioid misuse often traces its roots to medically valid pain management intervention. Increased awareness of addiction has led providers to look for effective alternatives. In the hospital setting, recent studies find Caldolor® might be one such option.
Following successful preclinical trials and FDA funding, Cumberland Pharmaceuticals is preparing to launch a new Phase II trial of ifetroban to treat cardiomyopathy in Duchenne Muscular Dystrophy patients.
Cumberland Pharmaceuticals recently announced the addition of Vibativ® (telavancin) to its growing product lineup. The Nashville-headquartered specialty pharmaceutical company entered into a definitive agreement to acquire Vibativ from Theravance Biopharma in the fourth quarter of 2018.
Nashville-based Cumberland Pharmaceuticals has announced expansion into oncology support with the launch of a new corporate division.
Nashville-based Cumberland Pharmaceuticals has entered a co-promotion agreement for Kristalose® within the United States with Poly Pharmaceuticals Inc., a privately held U.S. specialty pharmaceutical company.
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: